Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
Front Immunol 2025;16:1586792 doi: 10.3389/fimmu.2025.1586792
UPA has shown effectiveness in treating IMIDs like RA, axSpA, PsA, CD, and UC. Chai et al. evaluated evidence from a synthesis of RCTs and provided insights that may guide clinical decision-making and improve treatment outcomes for IMIDs. UPA effectively alleviated symptoms, reduced disease activity, and showed notable benefits in improving quality of life.
Chai et al. conducted a systematic review and meta-analysis that evaluated the efficacy and safety of UPA across multiple immune-mediated inflammatory diseases (RA, axSpA, PsA, CD, UC). Authors searched PubMed, Web of Science, and Embase, included only RCTs, assessed risk of bias, and performed pooled analyses.
Keywords:
